CIGNA members: Please note that you may receive a letter in the mail stating that The Dermatology Center of Indiana is no longer in your network. This communication from CIGNA is incorrect and we would like to reassure you that we are still in network with CIGNA. We look forward to continuing to service you and your family for all your dermatology needs.

2016

Psoriasis
Sponsor: AbbVie | Boehringer Ingelheim
BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
18 Years and Older
Phase: Phase 3
Start Date: February 2016
End Date: September 2017

Psoriasis
Sponsor: AbbVie | Boehringer Ingelheim
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
18 Years and Older
Phase: Phase 3
Start Date: February 2016
End Date: July 2018

Acne Vulgaris
Sponsor: Cassiopea SpA
An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris
9 Years and Older
Phase: Phase 3
Start Date: March 2016
End Date: December 2017

Actinic Keratosis
Sponsor: DUSA Pharmaceuticals, Inc.
Microneedle Lesion Preparation Prior to ALA-PDT for AK on Face
18 Years and Older
Phase: Phase 2
Start Date: March 2016
End Date: September 2016

Atopic Dermatitis
Sponsor: Pfizer
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
18-75 Years
Phase: Phase 2
Start Date: April 2016
End Date: May 2017

Plaque Psoriasis
Sponsor: Eli Lilly and Company
A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis
18-75 Years
Phase: Phase 2
Start Date: September 2016
End Date: February 2019